Puretech Health Stock Price, News & Analysis

PureTech Health plc (Nasdaq: PRTC) reported its half-yearly results for the six months ending June 30, 2021. The company holds $439.8 million in consolidated cash and cash equivalents. With a strong clinical pipeline, including 25 therapeutic candidates, six are in clinical development. Recent advances include LYT-100 trials for Long COVID and lymphedema. The merger of Gelesis with Capstar is set to enhance its public trading. PureTech maintains equity in multiple Founded Entities with potential royalty income exceeding equity values.

PureTech Health (Nasdaq: PRTC) announced the presentation of the Phase 1 study results of LYT-100 at the European Respiratory Society Congress. This therapeutic candidate targets inflammation and fibrosis, showing favorable tolerability and pharmacokinetics. Results indicate a dose-proportional pharmacokinetic profile, with the potential for twice-daily dosing. PureTech has initiated further trials to explore higher doses. The company aims to position LYT-100 as a frontline treatment for interstitial lung diseases, including idiopathic pulmonary fibrosis and Long COVID complications.

PureTech Health (Nasdaq: PRTC) announced that its Founded Entity, Akili Interactive, has licensed technology from TALi to address early childhood attention impairments. This agreement is set to facilitate clinical trials in pediatric ADHD in the U.S. and pursue FDA regulatory clearance. Akili expects the deal to enhance its digital therapeutics portfolio, leveraging TALi's technology to improve attention in children aged 3-8. The deal includes $37.5M in milestone payments and royalties, aiming to expand Akili's market presence in prescription digital therapeutics.

PureTech Health (Nasdaq: PRTC) has appointed Julie Krop, M.D. as Chief Medical Officer, overseeing clinical development for its expanding pipeline. Dr. Krop brings extensive experience, having led the development of eight therapeutics reaching Phase 3, with three achieving FDA approval. Her expertise will be pivotal for advancing the lead program, LYT-100, towards potential registration in treating idiopathic pulmonary fibrosis. PureTech has a robust pipeline of 26 therapeutic candidates, including two with regulatory approvals.

PureTech Health (Nasdaq: PRTC) announced that Imbrium Therapeutics has exercised a license option to develop LYT-503/IMB-150, a non-opioid candidate for interstitial cystitis/bladder pain syndrome. This collaboration includes a $6.5 million option exercise payment, with potential for up to $53 million in milestone payments and royalties on sales. An IND application for LYT-503/IMB-150 is expected in early 2022. The drug aims to target inflamed bladder tissue while minimizing systemic exposure, addressing a significant unmet medical need.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) plans to announce its half-yearly results for the six months ended June 30, 2021, on August 24, 2021. A presentation and conference call for analysts will occur at 9:00am EDT / 2:00pm BST on the same day. PureTech is a clinical-stage biotherapeutics company focused on developing innovative treatments for severe diseases across various medical fields. The company’s pipeline includes 26 therapeutics and candidates, with two securing FDA clearance and European marketing authorization. More details can be found on their website.

PureTech Health (Nasdaq:PRTC) announced that its Founded Entity, Akili Interactive, has launched new gaming features for its FDA-cleared EndeavorRx treatment aimed at children with ADHD. This update enhances user engagement and personalization without altering its patented core technology, the Selective Stimulus Management Engine (SSME™). These improvements are informed by user insights and latest trends in gaming development, marking a significant step in Akili's go-to market strategy to scale usage among families and healthcare professionals.

PureTech Health (Nasdaq: PRTC) announces that its Founded Entity, Vedanta Biosciences, has completed a $68 million Series D financing led by Magnetar Capital and includes a $25 million investment from Pfizer. The funds will support Vedanta's clinical trials, including advancing VE303 into a Phase 3 trial for Clostridioides difficile infection and initiating a Phase 2 trial for VE202 in ulcerative colitis. Vedanta's pipeline focuses on defined bacterial consortia therapies, addressing various diseases, with results expected in Q3 2021.

PureTech Health plc (Nasdaq: PRTC) announced a definitive agreement for its Founded Entity, Gelesis, Inc., to merge with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR). This transaction aims to list the combined company on the NYSE under the symbol 'GLS' and has an implied enterprise value of approximately $1.0 billion. Gelesis expects to secure up to $376 million in gross proceeds, primarily for the commercial launch of its FDA-cleared weight management product, Plenity. This merger showcases PureTech's unique model for creating value through its Founded Entities.